Sort
51,593 grants matching “hepatitis”
Clinical Research Network in Non-Alcoholic Steatohepati*
$1,170,878James A Tonascia · Johns Hopkins University · U01 · FY2006 · DK
Immunology of Acute and Chronic Viral Hepatitis
$1,170,726Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Pittsburgh Liver Research Center
$1,170,620Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · P30 · FY2023 · DK
Pittsburgh Liver Research Center
$1,170,620Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · P30 · FY2019 · DK
Pittsburgh Liver Research Center
$1,170,620Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · P30 · FY2022 · DK
Pittsburgh Liver Research Center
$1,170,620Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · P30 · FY2021 · DK
Molecular Pathogenesis of Digestive Diseases
$1,170,000Harry Bernard Greenberg · Stanford University · P30 · FY2010 · DK
Combinational Immunotherapies to Amplify Vaccine Induce*
$1,169,956Elizabeth Marion Jaffee · Johns Hopkins University · U19 · FY2006 · CA
Molecular Subtypes for Targeted Therapies in Alcoholic Hepatitis
$1,169,040Ramon Bataller · Univ Of North Carolina Chapel Hill · U01 · FY2015 · AA
Clinical Research on Nonalcoholic Fatty Liver Disease
$1,168,644Joel Edward Lavine · Columbia University Health Sciences · U01 · FY2012 · DK
Molecular Mechanisms of TGF-beta Signaling Pathway
$1,168,556Ying Zhang · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.
$1,168,511Georg Michael Lauer · Massachusetts General Hospital · R01 · FY2024 · AI
Regulation of Liver by Nuclear Ca2+ Signaling
$1,168,009Michael H Nathanson · Yale University · P01 · FY2006 · DK
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV
$1,166,670Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2021 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV
$1,166,670Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2019 · AI
Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV
$1,166,670Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2020 · AI
SARS-COV-2 Screening in Dialysis Facilities: Building an Optimal Strategy to Protect High Risk Populations
$1,166,528Shuchi Anand · Stanford University · U01 · FY2022 · AI
Miami Treatment and Prevention Clinical Trials Unit (CTU)
$1,166,422Margaret A Fischl · University Of Miami School Of Medicine · UM1 · FY2017 · AI
Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings
$1,165,515Frederick Lewis Altice · Yale University · R01 · FY2022 · DA
The Cleveland Digestive Diseases Research Core Center (DDRCC)
$1,164,000Fabio Cominelli · Case Western Reserve University · P30 · FY2020 · DK
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
$1,163,856Richard Joseph Johnson · Colorado Research Partners, Llc · U01 · FY2022 · AA
Regulation of stem cell development during tissue remodeling
$1,163,470Yun-Bo Shi · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD
Regulation of Liver by Nuclear Ca2+ Signaling
$1,163,226Michael H Nathanson · Yale University · P01 · FY2009 · DK
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
$1,163,175Jose Szapocznik · University Of Miami School Of Medicine · UG1 · FY2019 · DA
Nox family NADPH oxidases: roles in innate immunity and inflammatory disease
$1,163,165Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI